To review some of the factors that influence the cost of pharmaceuticals and the delivery of pharmaceutical care as well as some possible measures for decreasing these costs.
DATA SYNTHESIS:
Clinical studies have been selected to illustrate factors that may add to the overall cost of pharmaceutical care.
CONCLUSIONS:
Because of the perceived problems resulting from the introduction of new, expensive pharmaceuticals, possible means of controlling the costs of individual products are discussed. In addition, recommendations for achieving cooperation between pharmaceutical manufacturers and pharmacy practitioners in demonstrating the cost-effectiveness of new products are provided.
Get full access to this article
View all access options for this article.
References
1.
VagelosPR. Are prescription drug prices high?Science1991; 252: 1080–4.
2.
Prescription and OTC pharmaceuticals. FDC Reports1992; 54 (1):15–6.
3.
Prescription and OTC pharmaceuticals. FDC Reports1992; 54 (13):13.
4.
DunkleLMArvinAMWhitleyRJRotbartHAFederHMFeldmanS. A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med1991; 325: 1539–44.
5.
TopolEJ. Which thrombolytic agent should we choose?Prog Cardiovasc Dis1991; 34: 165–78.
6.
TognoniGFrescoCFranzosiMGMaggioniAP. Thrombolysis in acute myocardial infarction. Chest1991; 99 (suppl):121S–7S.
7.
WhiteHDRiversJTMaslowskiAHOrmistonJATakayamaMHartHH. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N Engl J Med1989; 320: 817–21.
8.
Gruppo Italiano per lo Studio della Sopravvivenza Nell'Infarto Miocardico (GISSI-2).A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet1990; 336: 65–71.
9.
The International Study Group.In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Lancet1990; 336: 71–5.
10.
Third International Study of Infarct Survival Collaborative Group (ISIS-3).A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet1992; 339: 753–69.
11.
NemunaitaisJRabinoweSNSingerJWBiermanPJVoseJMFreedmanAS. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med1991; 324: 1773–8.
12.
PowlesRSmithCMilanSTreleavenJMillarJMcElwainT. Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukemia: Double-blind, placebo controlled trial. Lancet1990; 336: 1417–20.
13.
CrawfordJOzerHStollerRJohnsonDLymanGTabbaraI. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med1991; 325: 164–70.
14.
BozzetteSALarsenRAChiuJLealMAEJacobsenJRothmanP. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. N Engl J Med1991; 324: 580–4.
ZieglerEJFisherCJSprungCLStraubeRCSadoffJCFoulkeGE. Treatment of gram-negative bacteremia and septic shock with a HA-1A human monoclonal antibody against endotoxin. N Engl J Med1991; 324: 429–36.
17.
LeiboviciLGreenshtainJCohenOMorFWysenbeekAJ. Bacteremia in febrile patients—a clinical model for diagnosis. Arch Intern Med1991; 151: 1801–6.
18.
WenzelRPAndrioleVTBartlettJGBattMDBullockWECobbsCG. Antiendotoxin monoclonal antibodies for gram-negative sepsis: Guidelines from the IDSA. Clin Infect Dis1992; 14: 973–6.
19.
VerstraeteMBoryMCollenDErbelRLennaneRJMatheyD. Randomized trial of intravenous recombinant tissue plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet1985; 1: 842–7.
20.
BuxtonMJDuboisDJTurnerRRSculpherMJRobinsonPASearcyC. Cost implications of alternative treatments for AIDS patients with cryptococcal meningitis. Comparison of fluconazole and amphotericin B-based therapies. J Infect1991; 23: 17–31.
21.
BulpittCJFletcherAE. The measure of quality of life in hypertensive patients: A practical approach. Br J Clin Pharmacol1990; 30: 353–64.
22.
FinleyRS. Measuring the cost-effectiveness of hematopoietic growth factor therapy. Cancer1991; 67 (suppl):2727–30.
